shutterstock_159488225

Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

pharmafile | January 31, 2020 | News story | Medical Communications, Research and Development Bayer, orion, pharma 

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult male patients.

The data showed that the drug, when combined with androgen deprivation therapy (ADT), demonstrated a “significant improvement” in overall survival benefit compared to placebo with ADT.

This benefit bolsters previous data supporting the combo’s efficacy in metastasis-free survival compared to the placebo combo. However, thus far, the combo has not produced mature data on its benefit in overall survival; these data as well as those on additional endpoints were confirmed to be in the pipeline to be presented at an upcoming scientific meeting.

The combo has already secured approval in the US, Brazil and Japan for this indication.

Matt Fellows

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content